Monitoring Agency Report for the quarter ended December 31, 2025
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Suven Life Sciences has filed the quarterly Monitoring Agency Report for Q3 FY26 (quarter ended December 31, 2025) with the stock exchanges, as required under SEBI rules. This is a routine compliance filing mandated when a company raises capital through routes such as preferential allotment, rights issue, or QIP, where an independent monitoring agency (usually a scheduled bank) must track how the proceeds are being utilised. The report covers deployment of funds raised from an earlier capital raise against the originally stated objects during the October–December 2025 quarter. Shareholders can refer to the attached PDF on the NSE/BSE corporate filings page for the exact utilisation figures, any deviations flagged, and the monitoring agency's comments.
This is generally a procedural compliance filing with little direct impact on the stock price. However, if the report flags material deviations or misuse of funds, it would be a negative signal for investors — worth a quick look at the attached PDF.